Tildrakizumab effective for moderate-to-severe chronic plaque psoriasis

  • Papp KA & al.
  • J Eur Acad Dermatol Venereol
  • 5 Mar 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pooled data from 3 randomised controlled trials confirmed the efficacy of tildrakizumab in patients with moderate-to-severe chronic plaque psoriasis.
  • Higher doses of tildrakizumab may improve efficacy in heavier patients.

Why this matters

  • Pooling data allow for more robust assessment of subgroups vs individual trials.

Study design

  • Analysis of pooled data of 2081 patients with plaque psoriasis from 3 randomised trials.
  • Patients received tildrakizumab 100/200 mg or placebo/etanercept.
  • Primary endpoint: proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 16.
  • Funding: Merck & Co., Inc., Kenilworth, NJ, USA.

Key results

  • At week 12, proportions of PASI 75 responders were significantly higher with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs placebo (5.6%; P<.0001>
  • Proportion of patients achieving PASI 90, PASI 100 and Physician’s Global Assessment (PGA) ‘clear’ or ‘minimal’ were significantly higher with tildrakizumab vs placebo (P<.0001>
  • Responses increased from week 12 to 28.
  • Week 12 PASI and PGA responses to tildrakizumab vs placebo were numerically greater in patients with lower vs higher bodyweight.
  • Responses for patients with higher bodyweight were generally better with tildrakizumab 200 mg than with tildrakizumab 100 mg vs placebo or etanercept.
  • Week 12 PASI 75 responses vs placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics.

Limitations

  • Long-term data not available.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit